Allergo Journal International最新文献

{"title":"Allergen immunotherapy in children and adolescents: current aspects 2024","authors":"Michael Gerstlauer MD","doi":"10.1007/s40629-024-00316-6","DOIUrl":"10.1007/s40629-024-00316-6","url":null,"abstract":"<p>Allergen immunotherapy (AIT) is a proven treatment for allergic diseases such as allergic rhinoconjunctivitis (ARC), allergic asthma (AA) and insect sting allergy. Particularly in children and adolescents, who have a high prevalence of these diseases, AIT plays a crucial role in not only alleviating symptoms but also influencing the natural course of the disease. This article examines the use and importance of AIT in children and adolescents in Germany in the final phase of the Therapy Allergen Ordinance (TAV). The focus is on the efficacy and safety of the therapy, as well as the approval of the respective therapeutic allergens for the respective age group.</p>","PeriodicalId":37457,"journal":{"name":"Allergo Journal International","volume":"34 4","pages":"89 - 94"},"PeriodicalIF":0.0,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s40629-024-00316-6.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145161890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of dietary counselling on allergic reactions in children with food allergy","authors":"Julia Eisenblaetter,&nbsp;Nia Stephens-Metcalfe,&nbsp;Andre Meichtry,&nbsp;Klazine van der Horst,&nbsp;Caroline Roduit,&nbsp;Alice Koehli,&nbsp;Felicitas Bellutti Enders,&nbsp;Isabel Skypala,&nbsp;Mary Hickson","doi":"10.1007/s40629-024-00314-8","DOIUrl":"10.1007/s40629-024-00314-8","url":null,"abstract":"<p>Dietary counselling in the field of food allergy aims primarily to empower individuals to prevent allergic reactions, but its impact on allergic reactions remains unclear. This study examined the impact of dietary counselling and other factors on allergic reactions in children with food allergies.</p><p>In a multicentre study, parents of children (0–10 years) recently diagnosed with food allergies completed online questionnaires collecting data on subsequent allergic reactions. Data were collected at baseline and at 3, 6 and 12 months postdiagnosis. We fitted a negative binominal model to the data in order to quantify effects of counselling, time period and multiple food allergies on food allergy reaction rates.</p><p>Among the 48 enrolled children, 31 encountered a total of 85 food allergic reactions. The monthly reaction rate decreased from 0.28 in the first 3 months to 0.07 between 6 and 12 months. Children receiving counselling from a dietitian demonstrated a lower ratio (incidence rate ratio [IRR] = 0.37, confidence interval [CI] 0.19–0.72, <i>p</i> = 0.004). Those with more than three food allergies have an increased ratio compared to those with one to two food allergies (IRR = 6.18, CI 2.75–3.89, <i>p</i> &lt; 0.001).</p><p>Individual dietary counselling has the potential to prevent subsequent allergic reactions after diagnosis as it reduced the risk of allergic reactions by 63%. This impact might be most pronounced in the early months following diagnosis. Children with multiple food allergies are at a higher risk of allergic reactions and should, therefore, be prioritized to receive dietary counselling.</p>","PeriodicalId":37457,"journal":{"name":"Allergo Journal International","volume":"34 5","pages":"149 - 157"},"PeriodicalIF":0.0,"publicationDate":"2024-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s40629-024-00314-8.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145169728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recommendations for patch testing with patient’s own materials in occupational dermatology","authors":"Cara Bieck,&nbsp; Lara Obermeyer,&nbsp; Katja Dicke,&nbsp;Antje Alberts,&nbsp; Christoph Skudlik,&nbsp; Swen Malte John,&nbsp; Richard Brans","doi":"10.1007/s40629-024-00315-7","DOIUrl":"10.1007/s40629-024-00315-7","url":null,"abstract":"<div><p>Allergic contact dermatitis is one of the most common occupational skin diseases. Due to the limited availability of commercial patch test preparations, patch testing patient’s own material (POM) is of great importance in the diagnosis of occupational contact dermatitis. In a research project (FB 317b) funded by the German Social Accident Insurance (DGUV), a comprehensive assessment of the quality of patch testing with POM in individuals with suspected occupational skin diseases was carried out for the first time in Germany. The initial results show considerable deficiencies in the documentation and in some cases also in the performance of patch testing POMs. Therefore, recommendations for patch testing POM and in particular patch testing with workplace materials are presented.</p></div>","PeriodicalId":37457,"journal":{"name":"Allergo Journal International","volume":"34 3","pages":"69 - 75"},"PeriodicalIF":0.0,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s40629-024-00315-7.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143883591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"IgE immunoadsorption: technical background, functionality, and first clinical experience","authors":"Lucia Lo Scalzo MD,&nbsp;Maddalena Sciannamea MD,&nbsp;Arianna Cafarotti MD,&nbsp;Lamia Dahdah MD,&nbsp;Ludger Klimek MD PhD,&nbsp;Stefania Arasi MD PhD MSc","doi":"10.1007/s40629-024-00311-x","DOIUrl":"10.1007/s40629-024-00311-x","url":null,"abstract":"<p>The prevalence of allergic diseases has risen in the 21st century, drawing attention to specific therapeutic and preventive strategies. Due to the key role of immunoglobulin E (IgE) in the development of allergic reactions, IgE represents a key target treatment. In this scenario, IgE immunoadsorption (IgE-IA) has been investigated as a procedure that selectively removes circulating IgE antibodies from the bloodstream of patients with atopy.</p><p>This narrative review aims to critically summarize the current insights regarding IgE-IA in the context of the management of allergic diseases, ranging from the rationale to the technical aspects, as well as the benefits and unmet needs.</p><p>IgE-IA might be a treatment strategy in well-selected patients with allergic diseases. IgE depletion through sessions of IgE-IA results in immediate clinical improvement and might be useful in acute situations when a rapid clinical response is required or when classic approaches are contraindicated or ineffective. Due to the reduced effectiveness over time, IgE-IA could be a valid first approach before starting another IgE depletion therapy, such as omalizumab, when its commencement would otherwise be contraindicated by too-high serum IgE levels.</p><p>Overall, IgE-IA is safe and well tolerated; however, this procedure is currently difficult to implement in routine clinical practice because of costs, time demands, need for hospitalization, and the invasiveness of the procedure, with the associated risks related to the necessity of venous catheterization.</p>","PeriodicalId":37457,"journal":{"name":"Allergo Journal International","volume":"34 5","pages":"140 - 148"},"PeriodicalIF":0.0,"publicationDate":"2024-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s40629-024-00311-x.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145170040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sensitizations to pollen differ between Central European and Sub-Saharan African atopic dermatitis patients","authors":"Danielle Fehr,&nbsp;Muriel Rentschler,&nbsp;Fandresena Sendrasoa,&nbsp;Nick Li,&nbsp;Anna White,&nbsp;Meike Distler,&nbsp;Claudia Lang,&nbsp;Gloria Masenga,&nbsp;Nelson Mosha,&nbsp;George Semango,&nbsp;Clara Clemens,&nbsp;Tahinamandranto Rasamoelina,&nbsp;Abel Hermann Soankasina,&nbsp;Fahafahantsoa Rapelanoro Rabenja,&nbsp;Daudi Mavura,&nbsp;John Elisante Masenga,&nbsp;Peter Schmid-Grendelmeier,&nbsp;Marie-Charlotte Brüggen MD PhD","doi":"10.1007/s40629-024-00313-9","DOIUrl":"10.1007/s40629-024-00313-9","url":null,"abstract":"<p>Atopic dermatitis (AD) is often associated with allergic comorbidities, such as allergic asthma or allergic rhinoconjunctivitis (ARC). Sensitizations to pollen can directly impact AD, as patients can experience exacerbation during pollen season. This study aims to gain more insights into the pollen sensitization patterns of AD patients in Central Europe compared with sub-Saharan Africa (SSA).</p><p>We performed a case–control study involving a total of 90 participants: 20 AD patients and 10 healthy controls (HC) each from Switzerland (CH), Tanzania (TZ), and Madagascar (MD). We collected clinical data and serum samples and performed a multiplex IgE test (ALEX² Allergy Explorer, MacroArray Diagnostics, Vienna, Austria).</p><p>The prevalence of ARC and asthma in AD patients was similar in all countries (ARC: 60% TZ, 70% CH, 75% MD; asthma: 25% TZ, 30% CH, 20% MD). Total IgE levels were significantly higher in both SSA HC populations compared with the Swiss HC. The analysis of specific IgE levels revealed major differences in sensitization patterns between Africa and Europe, especially regarding grass pollen allergens. Swiss AD patients were sensitized to various grass pollen such as Bahia grass, Bermuda grass, common reed, perennial ryegrass, rye, and timothy grass. However, these allergens were irrelevant in the SSA population: no AD patient or HC subject was sensitized to the tested grass pollen.</p><p>The considerably different sensitization patterns between European and SSA AD patients warrant the development of allergy testing and desensitization therapies tailored to the African setting. Therefore, there is a need to characterize local pollen types and counts.</p>","PeriodicalId":37457,"journal":{"name":"Allergo Journal International","volume":"34 2","pages":"46 - 55"},"PeriodicalIF":0.0,"publicationDate":"2024-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s40629-024-00313-9.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143632414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Requirements for regulatory acceptance of biomarkers","authors":"Hilke Zander,&nbsp;Jörg Engelbergs","doi":"10.1007/s40629-024-00312-w","DOIUrl":"10.1007/s40629-024-00312-w","url":null,"abstract":"<p>Generally, biomarkers could increase the success rate of medicinal product developments and as a consequence accelerate the availability of new therapeutics with an improved benefit–risk relationship. Therefore, patient identification based on predictive biomarkers is becoming increasingly important in all therapeutic areas [1]. The increasing use of predictive biomarker-guided-personalized (precision) medicine warrants the discovery of novel biomarkers as measurable indicators of physiopathological conditions [2]. Biomarkers can be used for diagnostics and prognostics, monitoring disease progression, but also to select the most effective therapy and to predict the treatment outcome [3, 4]. The current article provides a short focus on the regulatory definition of a biomarker and the biomarker qualification process of the European Medicines Agency (EMA). With the evolving landscape, the new Regulation (EU) 2017/746 on in vitro medical devices (IVDR) [5] introduces important changes in the EU legal framework for IVDs especially by legally defining for the first time “companion diagnostic” devices (CDx). Challenges in the codevelopment of CDx and medicinal products are highlighted to provide scientific–regulatory considerations in this complex regulatory field.</p>","PeriodicalId":37457,"journal":{"name":"Allergo Journal International","volume":"33 8","pages":"309 - 312"},"PeriodicalIF":0.0,"publicationDate":"2024-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s40629-024-00312-w.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142714360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of obesity on allergic respiratory diseases and on mental and cognitive performance","authors":"Nora Geissler,&nbsp;Erika Garner-Spitzer,&nbsp;Aleksandra Inic-Kanada,&nbsp;Daniela D. Pollak,&nbsp; Ursula Wiedermann","doi":"10.1007/s40629-024-00308-6","DOIUrl":"10.1007/s40629-024-00308-6","url":null,"abstract":"<p>Obesity and allergies are among the most common diseases of our civilization. Given the simultaneous rise in the prevalence of these diseases in recent years, a potential causal link between the two has been proposed. In particular, obese patients are at an increased risk of developing bronchial asthma, likely due to mechanical restrictions but also to metabolic changes that adversely affect immune function. Neuroscience studies have also shown that obesity can lead to impaired brain function and mental health. In the following review, we will take a closer look at our studies that focus on the influence of obesity on allergic diseases and cognitive performance.</p><p>Both human studies and animal models (mice) have shown that obesity leads to increased allergic responses in the airways. Our studies in a mouse model of obesity confirm that an obese phenotype is associated with increased allergic sensitization and manifestation. These changes are associated with significant shifts in the composition of the gut microbial flora. The microbiome changes are further associated with allergic airway inflammation and an increased incidence of T helper 1 (Th1) type pulmonary macrophages. Interestingly, despite the changes in the microbiome, it is possible to effectively prevent allergy development by inducing oral tolerance. Furthermore, it was observed that obese mice show increased signs of anxiety and depression, as well as reduced cognitive performance.</p><p>Obesity is a complex metabolic disease that significantly impacts our body’s gut microbiome and immune system, resulting in an increased incidence of allergic asthma and neurological/psychological changes. Attention should be given to both the prophylactic and therapeutic measures to mitigate the impact of obesity, including oral tolerance for managing existing allergic diseases.</p>","PeriodicalId":37457,"journal":{"name":"Allergo Journal International","volume":"33 7","pages":"247 - 251"},"PeriodicalIF":0.0,"publicationDate":"2024-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s40629-024-00308-6.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142447335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"One health: the impact of environment, detergents and hygiene on barrier, microbiome and allergy","authors":"Hanna Mayerhofer,&nbsp; Isabella Pali-Schöll PhD","doi":"10.1007/s40629-024-00307-7","DOIUrl":"10.1007/s40629-024-00307-7","url":null,"abstract":"<p>A variety of body surfaces, such as skin and mucosal membranes—from the nasopharyngeal area to the lungs, uterus, vaginal area, and digestive tract—contain complex microbial ecosystems that are tailored to the specifics of the respective niche [1].</p><p>The so-called dysbiosis—a disadvantageous change in the composition of the microbiome—is associated with the pathogenesis of a variety of diseases [2]. Gastrointestinal as well as cardiovascular, metabolic, neurodegenerative, psychological, oncological, and also allergic diseases have been linked to microbial dysbiosis. Susceptibility to allergies can be due to genetic predisposition; in addition, extrinsic factors from today’s lifestyle increasingly contribute to microbiome changes, but also to the disruption of the skin and mucosal barrier and thus to the development of allergies [3].</p><p>Gisela, a fictional farmer, guides us through this review. She is representative of adults and children of all genders in industrialized countries. During her daily routine, the skin and mucosal microbiome is influenced by a variety of exogenous factors. These include everyday personal hygiene products, detergents for laundry and dishes, food, medication, animal contact, and exposure to various outdoor environments. Gisela’s daily routine will illustrate how the human microbiome and the skin barrier are modified in positive or negative ways, and how this could influence the development of allergies. Furthermore, potential measures for the prevention and management of dysbiosis will be discussed in terms of examples of alternative products and behaviors.</p>","PeriodicalId":37457,"journal":{"name":"Allergo Journal International","volume":"33 7","pages":"252 - 262"},"PeriodicalIF":0.0,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s40629-024-00307-7.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142447408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Discharge management after anaphylaxis","authors":"Valentina Faihs,&nbsp; Johannes Ring,&nbsp;Knut Brockow,&nbsp;Kirsten Beyer,&nbsp;Ernst Rietschel,&nbsp;Sabine Schnadt,&nbsp;Britta Stöcker,&nbsp;Regina Treudler,&nbsp;Margitta Worm,&nbsp;Ludger Klimek","doi":"10.1007/s40629-024-00306-8","DOIUrl":"10.1007/s40629-024-00306-8","url":null,"abstract":"<div><p>People who have suffered from anaphylaxis often experience far-reaching consequences in everyday life. Unfortunately, discharge management after successful acute treatment is often still inadequate. In order to prevent further reactions in the future and improve the patient’s quality of life, there are several points that should be addressed or followed upon discharge from acute treatment. These include taking a detailed medical history to identify potential triggers, documenting the acute therapy, recommending further allergological assessment and prescribing an emergency kit for self-help including an adrenaline auto-injector—with education and practice on how to use it, including a written emergency plan. In addition, recommendations for avoiding potential triggers and information on patient organizations are helpful. This article aims to provide an up-to-date overview of discharge management after successful acute treatment of anaphylaxis. Remember: “After anaphylaxis also means potentially before the next anaphylaxis.”</p></div>","PeriodicalId":37457,"journal":{"name":"Allergo Journal International","volume":"33 8","pages":"275 - 281"},"PeriodicalIF":0.0,"publicationDate":"2024-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s40629-024-00306-8.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142714438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of IgG1 and IgG4 as dominant IgE-blocking antibodies during allergen immunotherapy","authors":"Barbara Bohle PhD","doi":"10.1007/s40629-024-00309-5","DOIUrl":"10.1007/s40629-024-00309-5","url":null,"abstract":"<p>Allergen immunotherapy (AIT) is the only treatment that modifies the allergic response to allergens. One immune mechanism associated with a reduction in clinical symptoms is the induction of immunoglobulin E (IgE)-blocking antibodies. In particular, AIT-induced allergen-specific IgG4 antibodies were regarded a candidate biomarker for clinical efficacy. With the knowledge that not all AIT-induced allergen-specific IgG antibodies bear blocking bioactivity, different in vitro assays became popular to assess the blocking capacity of sera collected during and after AIT. Their measuring principles vary in the detection of the prevention of IgE-binding to allergen or of allergen interactions with IgE bound to high-affinity Fc epsilon receptors on the surface of effector cells. More recently, the contribution to IgE-blocking of other isotypes that arise in the course of AIT, e.g., IgG1 and IgA, was confirmed. The results indicated that different isotypes of allergen-specific antibodies serve as dominant IgE-blocking factors in the course of AIT.</p>","PeriodicalId":37457,"journal":{"name":"Allergo Journal International","volume":"33 8","pages":"282 - 288"},"PeriodicalIF":0.0,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142714615","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}